us notice of allowance on key aod9604 patent

Metabolic Pharmaceuticals announced today that the US Patent Office has issued a
Notice of Allowance on its key obesity patent application, which confirms that the patent
will be granted covering Metabolic's AOD9604 obesity compound and a range of similar
compounds...............................
Metabolic has already been granted or allowed similar patent applications in Australia,
New Zealand and Russia and applications are pending in Europe, Japan, Canada, Brazil
and China.................................